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ABSTRACT 
Background 
Colorectal cancer is common and the standard surgical treatment is open 
resection (OS) but laparoscopic surgery (LS) maybe an alternative.  In 2000, a 
Health Technology Assessment (HTA) review found little evidence on costs 
and cost-effectiveness comparing the two methods.  The evidence base has 
since expanded and this study systematically reviews the economic evaluations 
on the subject published since 2000. 
 
Methods 
Systematic review of studies reporting costs and outcomes of LS vs. OS for 
colorectal cancer. National Health Service Economic Evaluation Database (NHS 
EED) methods for abstract writing were followed.  Studies were summarised 
and incremental cost-effectiveness ratios (ICER) for common outcomes 
calculated. 
 
Results  
Five studies met the inclusion criteria.  LS generally had higher health care 
costs.  Most studies reported longer operational time and shorter length of stay 
and similar long-term outcomes with LS vs. OS.  Only one outcome, 
complications, was common across all studies but results lacked consistency 
(e.g. in two studies open surgery was less costly but more effective, in another 
laparoscopic surgery was less costly but more effective, and in the further two 
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laparoscopic surgery could potentially be cost effective depending on the 
decision-makers willingness to pay for the health gain). 
 
Conclusion 
The evidence on cost-effectiveness is not consistent. LS was generally more 
costly than OS.  However, the effectiveness data used in individual economic 
evaluation was imprecise and unreliable compared with data from systematic 
reviews of effectiveness. Nevertheless, short-term benefits of LS (e.g. shorter 
recovery) may make LS appear less costly when productivity gains are 
considered. 
 
 
KEYWORDS 
Economic evaluation, cost effectiveness, systematic review, laparoscopic 
surgery, colorectal cancer 
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1 Introduction 
 
Colorectal cancer is one of the most common cancers in the Western world and 
is the second most common malignancy in England and Wales in terms both of 
incidence and mortality.  Approximately 36,000 new cases were diagnosed in 
2002 and 17,000 people died from colorectal cancer in the same year.  About 
80% of all patients diagnosed with colorectal cancer (including some with 
advanced disease) undergo surgery.[1] 
 
Open resection is currently the standard method for surgical removal of 
primary colorectal tumours. Minimally invasive approaches to treat colorectal 
diseases were developed to take advantage of the benefits observed in 
laparoscopic procedures elsewhere in the gastrointestinal tract.[2] Laparoscopic 
surgery, includes total laparoscopic, laparoscopic assisted and hand assisted 
procedures. In practical terms a totally laparoscopic and laparoscopically-
assisted procedure are considered comparable because of the size of incisions 
involved. In the remainder of this paper laparoscopic and laparoscopically-
assisted surgery are referred to as laparoscopic surgery.  In hand assisted 
laparoscopic surgery (HALS), the surgeon inserts a hand into the abdomen 
while pneumoperitoneum is maintained. Some surgeons find this easier than 
laparoscopic surgery particularly in the transitional phase between 
conventional and laparoscopic surgery.  Advantages claimed for placing the 
hand in the abdomen include tactile feedback, the ability to palpate, blunt 
dissection, organ retraction, control of bleeding, and rapid organ removal.[3-5] 
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Laparoscopic surgery is less invasive and hence may lead to more rapid 
recovery from the operation but the potential impact on cure rates is unclear.  
The major concerns are that tumour recurrence might occur at port sites and 
that clearance of the tumour may be less complete than during open surgery.  It 
has also been suggested that the reduced trauma to tissues may lower 
disruption to the immune system and hence reduce the risk of recurrence.[6]  
Additionally, it has been argued that there are disadvantages of laparoscopic 
surgery relating to the longer length of the operation, the cost of materials, and 
the effect of surgeon experience on patient outcomes.   
 
Vardulaki and colleagues[7] conducted a review of studies comparing the costs 
of the laparoscopic surgery and open surgery in 2000, (there were no economic 
evaluations available at this time), as part of the health technology assessment 
review (TAR) carried out by the National Institute for Clinical Excellence. Eight 
studies met their inclusion criteria and they reported that there was no 
significant difference in costs between the two procedures in most studies.  
Differences in cost were driven mainly by the estimates of cost of 
hospitalisation and time in theatre which varied between studies. Moreover, 
Vardulaki and colleagues[7] conducted a costing exercise but did not combine data 
on costs with data on effectiveness in an economic evaluation to assess cost-
effectiveness.  In addition to this, the evidence base (for effectiveness and cost) 
was very limited as no studies reported long-term outcomes and economic 
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evidence was of limited quality. Therefore, in terms of efficiency no robust 
conclusions could be drawn from the HTA 2000 report.[7] 
 
Since 2000 the evidence base has expanded and experience with laparoscopic 
technique has increased.[1] The present study is a systematic review of the 
economic evaluations conducted as part of a health technology assessment on 
laparoscopic surgery for colorectal cancer conducted on behalf of the UK’s 
National Institute for Health and Clinical Excellence (NICE). Amongst other 
reasons, systematic reviews are important as they can establish whether 
scientific findings are consistent and can be generalisable to other populations 
and/or settings. Furthermore, explicit methods used in systematic reviews limit 
bias and improve reliability and accuracy of conclusions.  
 
The paper reports a systematic review of the economic evaluations of 
laparoscopic and/or hand assisted laparoscopic techniques compared to open 
surgery for the treatment of colorectal cancer. 
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2 Methods  
 
2.1 Search Strategies 
Studies that reported both costs and outcomes of laparoscopic and/or HALS 
techniques compared to open surgery for the treatment of colorectal cancer 
were sought from a systematic review of the literature.  No language 
restrictions were imposed but as this review is an update of an earlier review 
conducted in 2000, the searching was limited to studies available between 2000-
2005.   
 
Databases searched were Medline (2000 – May Week 2 2005), Embase (2000 - 
Week 21 2005), Medline Extra (23rd May 2005), Science Citation Index (2000 – 
27th May 2005), National Health Service Economic Evaluations Database -NHS 
EED- (May 2005), Health Technology Assessment (HTA) Database (May 2005), 
Health Management Information Consortium (2000 – May 2005) and Journals @ 
Ovid Full Text (2000 – July 2005 for selected surgical journals).  In addition, 
recent conference proceedings and reference lists of all included studies were 
scanned to identify additional potentially relevant studies. Other sources of 
information consulted included: references in relevant articles; selected experts 
in the field; references of consultees’ submissions to NICE.  Full details of the 
search strategies used are available from the authors.  
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2.2 Inclusion and exclusion criteria 
To be included, studies had to compare, in terms of costs and outcomes, 
strategies involving laparoscopic and/or HALS compared to open surgery for 
treatment of colorectal cancer.  Studies were included even if they made no 
formal attempt to relate cost to outcome data in a cost-effectiveness or cost-
utility analysis.  One reviewer assessed all abstracts for relevance and full 
papers were obtained for those that appeared potentially relevant. 
 
2.3 Data extraction strategy 
The following data were extracted for each included primary study using the 
framework provided for abstracts prepared for the NHS Economic Evaluation 
Database.[8]  
 
a) Study identification information: author and year, interventions studied, type of 
economic evaluation, country of origin and currency reported; b) the 
intervention, study design and main outcomes: fuller description of treatment, 
numbers receiving or randomised to each intervention, outcomes studied; c) 
Sources of data: effectiveness data, mortality and comorbidity (if measured), cost 
data, quality of life (if measured); d) methods and study perspective; e) results: 
costs, benefits, incremental cost-effectiveness/utility ratio (ICER), sensitivity 
analyses; f) additional comments relating to the design and reporting of the economic 
evaluation. 
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No primary outcome was specified although all outcomes were prespecified in 
a protocol developed before the study started.  Ideally all these measures might 
be synthesised into a single unitary measure such as quality adjusted life years 
(QALYs).  In absence of such outcomes, data were abstracted on the following 
outcomes: mortality, survival; disease free survival; recurrences and 
complications (this latter outcome was the only one common across all studies).    
 
2.4 Data synthesis 
In economic evaluations, as well as in other research areas, is very important to 
know which methods the authors used to develop their calculations and 
analyses, as the results could eventually vary widely according to different 
methodologies used.[9]  For instance, cost categories should be reported and it 
is desirable that health care resource used as well.  Moreover, no matter what 
methodology is used, any economic evaluation is subject to uncertainty. The 
uncertainty (e.g. the type and sequence of relevant events considered, 
variability in data, etc.), can be addressed by conducting different types of 
sensitivity analyses.[10]  Sensitivity analyses will tell the reader how reliable the 
results are.  
 
One economist assessed included studies using the NHS-EED guidelines for 
reviewers.[8] This guidelines address all the important issues that should be 
reported when conducting an economic evaluation in health care.  No attempt 
was made to synthesize quantitatively the primary studies that were identified.  
Data from all included studies were instead summarised and appraised in 
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order to identify common results, variations and weaknesses between studies.  
If a study did not report incremental cost effectiveness ratios (ICERs) but 
provided sufficient data then, where possible, the data were reanalysed to 
provide estimates of ICERs.  These ICERs are presented for the following 
clinical outcomes: mortality, survival; disease free survival; recurrences and 
complications. 
 
3 Results 
 
3.1 Number of studies identified  
As a result of the literature searches, 392 study hits after deduplication were 
screened (Figure 1). From these, a total of 41 studies were selected for full 
assessment. Of these 41 studies, three studies[11-13] met the inclusion criteria.  
Two additional unpublished papers (that have since been published) also 
meeting the inclusion criteria were obtained from experts in the field.[14,15] A 
further study that compared laparoscopic surgery against HALS and, as a 
consequence did not meet the inclusion criteria, was also identified.[16] 
  
3.2 Study identification and key elements 
Two studies compared laparoscopic colon resection with open colon resection 
in the treatment of colon cancer,[11,13] one of which focused on right 
hemicolectomy.[13] A further study compared laparoscopic-assisted with 
conventional open resection for rectosigmoid carcinoma,[12] and two compared 
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laparoscopic versus open resection for colorectal cancer.[14,15]  One of these 
was in the context of an enhanced recovery program.[15] 
 
Five studies were classified as cost-consequence analyses.  That is, costs were 
compared with various different measures of effectiveness.  Two were based on 
single centre RCTs[12,15], and two were based on multicentre RCTs.[11,14] The 
fifth study was based on a single centre cohort-matched study conducted in 
China (Table 1).[13]  Two studies considered costs from a societal 
perspective[11,15] while the others adopted a hospital perspective (Table 
1).[12,13]  Franks and colleagues described their study as a cost analysis but 
included data on outcomes sufficient to calculate ICERs.[14]  
 
The study by Franks and colleagues represented a preliminary analysis 
conducted on a subset of patients from the CLASICC trial[17] who had agreed 
to be included in the economic analysis.  The dates for data collection were not 
reported. The Swedish study collected data from January 1999 to May 2002;[11] 
the study by King and colleagues from January 2002 to March 2004,[15] the 
study by Leung and colleagues, conducted in Hong Kong, collected data from 
September 1993 to October 2002,[12] and the Chinese study from September 
2002 to February 2003.[13]  In all five studies costs were estimated prospectively 
from the same sample as that used for collecting the effectiveness data.[11-15] 
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3.3 Patient group, study sample and study design 
The sample sizes in four of the five studies were modest (Table 1).  In the cohort 
matched study, 30 patients with colon cancer underwent laparoscopic right 
hemicolectomy surgery and were matched with 34 patients who received open 
right hemicolectomy surgery.[13]  Patients for the open surgery group in this 
study were matched for gender, age, Dukes’ staging, tumour site, previous 
abdominal operation and extent of resection. 34 patients were randomly 
selected from 87 patients who underwent open surgery during the same period.  
 
The analysis in all studies was conducted on an intention to treat basis, 
however, the follow-up period as well as the outcome measures varied 
considerably between studies (Table 1). 
 
3.4 Methods of economic analysis 
The four trial based papers[11,12,14,15] presented details on which items were 
included in the cost calculations, but no details were reported in the non-
randomised study.[13] Such information is useful as data on resource use can 
help readers judge the applicability of the study to their setting.  Relatively 
good details of unit costs were presented in the Swedish and UK 
studies[11,14,15] while no unit costs were reported in the other two 
studies.[12,13] In economics, costs occurring into the future are given less 
weight than costs occurring now, i.e. they are discounted.  Discounting was 
performed only in the Swedish study while it was actually relevant in all 
studies with a follow-up greater than 12 months.  Indirect costs were calculated 
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in three of the studies using the human capital approach (time off paid 
work)[11,14,15] Three papers did not use any summary measure of health 
benefits[12,13,15] and left the results disaggregated. One study focused 
primarily on costs.[14] In the Janson and colleagues study, the mean cost per re-
operated patient for each arm of the trial was presented (although it is not 
reported in this paper).[11]  
 
As previously stated, uncertainty is pervasive in every economic evaluation. 
Therefore, authors should allow for this by conducting different types of 
sensitivity analyses. One-way sensitivity analysis was performed in three 
studies.[11,14,15] Changes in perioperative, equipment, recovery, ICU and 
hospital costs were considered in the study by Franks and colleagues.  They 
also considered a subgroup analysis by location of cancer (colon or rectum).[14] 
Cost per minute for the operating room, anaesthesia and recovery room time 
were explored in the Swedish study[11] while duration of in-patient stay and 
the consumption of community resources after discharge were explored in the 
Study by King and colleagues.[15] 
 
3.5 Cost effectiveness results from the included studies  
The results of the included studies are summarised in Table 2.  In Franks and 
colleagues, total costs, including productivity costs, for both the base-case and 
both subgroups were not significantly different between the laparoscopic and 
open groups, although the confidence interval was very wide (mean additional 
cost of laparoscopic surgery was £268, 95% CI: –690 to 1460). Productivity costs 
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were not a major determinant of this additional cost although hospitalisation 
costs (less for laparoscopic surgery) and costs for re-operations and other 
complications (greater for laparoscopic surgery) were.  Although there was no 
evidence of a statistically significant difference in clinical outcomes, confidence 
intervals would be sufficiently wide for clinically and economically important 
differences to exist.[14] 
 
In Janson and colleagues total costs, including productivity loss, were not 
significantly different between the laparoscopic surgery and open surgery.  
However, total costs, excluding productivity losses (that is cost to the healthcare 
system), were significantly higher for the laparoscopic surgery compared with 
open surgery (€9474 vs. €7235; P=0.018), as were the costs related to the first 
admission, and the costs of primary surgery.[11] 
 
In King and colleagues the results reflected the increased duration of 
laparoscopic procedures and also the increased use of disposable equipment in 
theatre.  However, in their analysis, King and colleagues found that these costs 
were more than offset by lower post-operative costs such as re-operations, and 
productivity cost savings resulting from the earlier return to usual activities.[15] 
 
Similarly, the health service costs from Leung and colleagues were also higher 
for laparoscopic surgery than for open surgery and this difference, as with the 
other two RCT-based analyses, was statistically significant (P<0.001).[12]  
15 
“Lap. surg. syst. review economic eval.” 
However, no significant difference was observed in the total cost of operation 
and drugs between the two groups in the Chinese study (Table 2 - CNY1000 
circa £65.8 - www.bloomberg.com  5/02/2007).[13] 
 
Overall, the magnitude of the mean additional cost of laparoscopic compared 
with open surgery varied considerably between studies.  For example the 
relative cost of laparoscopic surgery compared with open surgery varied 
between 95%(13) and 130%.[12] 
 
Table 3 reports the estimated ICERs for the different clinical outcomes.  Only 
one measure of effectiveness was common across all studies: major 
complications.   In terms of mortality (2 studies[11,12]) 5 year survival (1 
study[12]); 5 year disease free survival (1 study[12]) and recurrence (1 
study[12]) it is unlikely that in terms of mean differences costs and outcomes 
that laparoscopic surgery would be considered cost-effective.  However, 
confidence intervals would probably be wide enough to include clinically and 
economically important differences favouring either type of surgery.  Table 3 
also reports the number of complications (see Table 1 for types of 
complications) in each study. Only two studies reported P-values for the 
difference between the number of complications in the laparoscopic and open 
groups[13,15] and in this study the difference was not statistically significant. 
These results are in line with those of a recent systematic review of effectiveness 
conducted by Murray and colleagues.[1] Murray and colleagues considered 
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data from 18 randomised controlled trials (RCTs) of general good quality. The 
authors considered amongst other outcomes, the occurrence of complications 
such as anastomotic leakage, abdominal wound breakdown, incisional hernia, 
and wound and urinary tract infections. They found no statistically significant 
differences between open and laparoscopic surgery within these outcome 
categories, although confidence intervals were wide enough for clinically 
important differences to exist. 
 
Incremental costs per major complication avoided were calculated using the 
data from the original studies (Table 3). Based on mean data for costs and 
complications open surgery is dominant (i.e. less costly and more effective) in 
two studies[11] while in another, laparoscopic surgery was dominant.[15] A 
forth study laparoscopic surgery could avoid a major complication at a cost of 
CNY10,008,[13] (circa £659). Complications from surgery could be avoided at a 
cost of USD 76,872[12] (approximately £39,220) according to Leung and 
colleagues. Finally, using data from Franks and colleagues [13] on number of 
total complications, using laparoscopic surgery could avoid a complication at 
an extra cost of between £229,000 and £268,000.[14]   
 
One study conducted a subgroup analysis by location of disease (colon or 
rectum).[14] Overall, surgery for colon cancer was on average approximately 
£3000 less costly than rectal cancer regardless of the method of surgery.  For 
both subgroups the mean total costs including indirect costs were greater for 
17 
“Lap. surg. syst. review economic eval.” 
laparoscopic surgery although they were not statistically significant.  When 
indirect costs were excluded laparoscopic surgery was less costly for colon 
cancer but more costly for rectal cancer.  For colon cancer the main drivers of 
this cost difference was that the higher theatre cost was more than compensated 
by the reduced hospitalisation and complications cost.  For rectum cancer 
patients the higher operation cost for laparoscopic surgery was almost matched 
by the lower hospitalisation costs, but there was a statistically significant higher 
cost of complications following laparoscopic surgery (Table 4).  The sample 
sizes for these subgroup analyses were modest (between 230 and 222 for 
laparoscopic surgery and 118 to 112 for open surgery for colon and rectum 
cancer respectively) and it is unclear whether the differences in total costs were 
mostly associated with different risks of complications between the surgeries or 
different types of complication occurring.   
 
4 Discussion  
 
In the previous review conducted for NICE on this subject, there was no 
economic evaluations identified and therefore, no evidence reported on cost-
effectiveness. Full economic evaluations need to bring together costs and effects 
on order to provide information on efficiency; it is the interplay of costs and 
effects that is important. The HTA 2000[7] reported some evidence in costs (e.g. 
eight costing studies were identified), and provided an economic costing 
exercise but this in itself does not provide evidence on cost effectiveness. That 
review found no statistically significant differences in costs between open 
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surgery and laparoscopic surgery in the reviewed studies. However, it was 
clear from their effectiveness review[7] that length of stay was consistently 
shorter (although not always statistically significantly shorter) for laparoscopic 
surgery. 
 
Our study reports evidence on cost-effectiveness and not only on costs and 
effects separately. The four RCT-based analyses identified by this updated 
review appear to have statistically significant longer operating times for 
laparoscopic surgery.  This is consistent with the data in the recent review of 
effectiveness reported by Murray and colleagues,[1] even though, the study by 
Zheng and colleagues[13] reported no statistically significant difference. With 
respect to length of hospital stay this appeared to be longer in the open groups: 
again, a result consistent with the review of effectiveness reported in Murray 
and colleagues.[1] Overall in terms of these findings the results of the review 
presented in this paper are consistent with the earlier more limited findings of 
Vardulaki and colleagues.[7] Namely, Verdulaki and colleagues[7]  reported a 
operating time mean difference of 62 minutes (e.g. open shorter) and length of 
hospital stay of -2.14 days (e.g. open longer) between laparoscopic and open 
surgery, while Murray and colleagues[1] a weighted mean difference of 40 
minutes and -2.63 days, respectively.  Therefore, the trend in resource use in 
favour of laparoscopic surgery (shorter operating time difference and longer 
length of stay difference compare with open surgery) seems to exist but not 
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with the strength predicted by Verdulaki and colleagues[7] who concluded that 
the difference in cost is “expected to disappear in the next 5 years”.  
 
The mean total health care cost of laparoscopic appeared to be greater than 
open surgery in all studies except in King and colleagues.[15]  However, there 
was no evidence of a statistically significant difference in total health care cost 
between laparoscopic surgery and open surgery, although confidence intervals 
were wide.  
 
One concern with laparoscopic surgery is the conversion rate to open surgery. 
Conversions are likely to increase the total cost of laparoscopic surgery as a 
conversion increases operation time. Although as reported by Murray and 
colleagues,[1] the evidence for comparing converted, non-converted 
laparoscopic and open patients is limited. It is likely that as experience increases 
the rates of conversion would fall.  
 
The incremental cost per complication avoided, shown in the previous section, 
should be interpreted extremely cautiously. All the studies had relatively small 
sample sizes and differences in the number of complications (used as the 
effectiveness measure in these calculations) between laparoscopic surgery and 
open surgery were not statistically significant.  Furthermore, different types of 
complications might have different effects in morbidity and, therefore, quality 
of life. Using another measure of effectiveness within the economic evaluation 
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(e.g. QALYs) might overcome this problem. With respect to the estimates of 
complications the estimates of the individual studies are likely to be less reliable 
than estimates derived from the review of effectiveness provided by Murray 
and colleagues.[1]  Data from their review of effectiveness provides no evidence 
of a difference in complication rates, although confidence intervals were 
sufficiently wide enough for clinically important differences to exist.   
 
The measure of total cost used differed substantially between studies.  For 
example, Franks and colleagues,[14] Janson and colleagues[11] and King and 
colleagues[15] considered indirect costs while the other two studies considered 
only direct costs from surgery and hospital stay.[12,13] The costing 
methodology was also poorly described in these latter two studies.  For 
example Zheng and colleagues reported only final cost figures and provided no 
details on the way calculations were performed.[13] 
 
It is unclear the extent to which the costs from the three non-UK studies would 
be applicable to the UK.  One UK study had a very small sample size, and it 
was based on a single centre.[15] The second UK study had a much larger 
sample size and more precise estimates of cost.  However, both the rate of 
conversions from laparoscopic to open (30%) and the higher rates of 
complications following laparoscopic surgery would tend to increase the 
difference between laparoscopic and open surgery.   
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The relatively short follow-up in all studies indicates that a modelling exercise, 
using the best available effectiveness data with a longer time horizon (e.g. the 
time over which cost and effects may differ between the treatments), might add 
valuable information for decision-making. Such an exercise should follow the 
usual guidelines of good practice for conducting an economic 
evaluation.[9,15,18-20] Namely, incorporate the best available effectiveness 
evidence, include all relevant cost categories according to the perspective 
adopted, use a relevant measure of effectiveness (e.g. life years gained, quality 
adjusted life years), and incorporate discounting as the relevant time horizon 
for the analysis is likely to be longer than a year. This suggests that the best 
economic evidence should come from a well designed economic model which 
uses the best available data which has been systematically assembled. 
 
Recently, two model based economic evaluations have been published[22,23] 
that seem to move forward the cost effectiveness. Hayes and colleagues[23] 
developed a simple model and found laparoscopic surgery to be potentially 
cost-effective (e.g. mean incremental cost per QALY $70,389 – circa £28,296). 
However, their results were sensitive to assumptions on the time needed to 
resume normal activities (e.g. between 12 and 33 days), and the cost of 
disposable equipment used within laparoscopic surgery. Moreover, the authors 
conducted only one way sensitivity analyses. The study by de Verteuil and 
colleagues[23] reports a more sophisticated analysis based on a Markov model 
populated with data retrieved from systematic reviews of the literature. The 
22 
“Lap. surg. syst. review economic eval.” 
study managed to predict long term outcomes and concluded that laparoscopic 
surgery. The authors conducted several sensitivity analyses, including 
probabilistic sensitivity analysis. They concluded that laparoscopic surgery was 
more costly and has a likelihood of being considered cost effective of between 
30 and 80 percent, depending on assumptions made about survival (e.g. relative 
risk of 1.03 or 1 –equal–), and disease free survival (e.g. relative risk of 1.03 or 1 
–equal–).  
 
In addition to the studies comparing laparoscopic surgery with open surgery a 
further study was identified comparing conventional laparoscopic surgery with 
HALS.[16] The authors concluded, “Although it is a more aggressive 
procedure, HALS preserves the feature of minimally invasive approach, 
maintains all the oncological features of conventional laparoscopic surgery, and 
does not increase the cost.” 
 
Other relevant issues that influence the decision about whether or not to adopt 
LS are speed of patient recovery and surgeon training. Murray and 
colleagues[1] reported that laparoscopic surgery seems to offer patients some 
short term quality of life advantages without compromising safety or long term 
outcomes (at least up to three years). However, relatively few surgeons are 
trained in this form of surgery and this therefore limits access to laparoscopic 
surgery. Furthermore, a low conversion rate seems to be key for laparoscopic 
surgery to be beneficial and this depends on experience.[1] Should a decision be 
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taken to increase the use of laparoscopic surgery then training programmes 
need to be put in place,[1] and the cost implications of this need to be 
considered before making the final decision on which technology to adopt.   
 
5 Conclusions 
 
This study presents the overall evidence available on cost-effectiveness analyses 
of laparoscopic surgery for colorectal cancer compared to open surgery, based 
on a systematic review of the literature.  Laparoscopic surgery generally had 
higher health care costs than open surgery as the former seems to involve 
longer operation times and higher equipment costs, although including 
productivity gains from earlier recovery make laparoscopic surgery appear less 
costly.  However, the measurement and inclusion of such costs (indirect costs) 
in an economic evaluation is contentious.[18,19] 
 
With respect to effectiveness, the data used by the individual studies is likely to 
be imprecise and unreliable when compared to the data available from a recent 
systematic review of effectiveness.[1] Thus, the evidence provided by the 
included economic evaluations using longer-term outcomes such as survival is 
likely to be imprecise and unreliable. Two more recently and better designed 
economic evaluations add to the cost-effectiveness evidence. However, their 
results seem to ratify the need for more data on long-term performance. 
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Table 1 Characteristics of the included studies 
Study id Design Sample Follow-
up 
Perspective Endpoints 
Franks 
2005[14](UK) 
Multicentre 
RCT 
(CLASICC) 
Laparoscopic: 
452 
Open: 230 
3 months Stated as 
Hospital (NHS) 
but Societal 
None specified although 
rates and types of 
complications and re-
operations were 
assumed to be the same 
and were used to 
generate costs 
Janson 
2004[11](Sweden) 
Multicentre 
RCT (COLOR 
Trial) 
Laparoscopic: 
98 
Open: 112 
36 
months 
Societal.  
(Unit costs 
retrieved from 
a single centre) 
Complication rate (e.g. 
anastomotic leak, bowel 
perforation, wound 
rupture, ileus, post-
operative bleeding, 
incarcerated abdominal 
hernia, endoscopic 
dilation, closure loop 
ileostomy); Re-
operations; Mortality; 3-
year survival 
King 2005[15] 
(UK) 
Single centre 
RCT 
Laparoscopic: 
43 
Open: 19 
3 months Societal Requirement of opioid 
analgesia; Anti-emetic 
administration; Major 
morbidity (e.g. 
haemorrhage, 
anastomatic leak, 
wound dehiscence and 
sepsis requiring at least 
high dependency 
support)-; Hospital stay; 
Length of stay for 
readmissions; Mortality 
Leung 2004[12] 
(Hong Kong) 
Single centre 
RCT 
Laparoscopic: 
203 
Open: 200 
52.7 
months 
(mean)  
49.2 
months 
(mean) 
 
Hospital Duration of operation; 
Blood loss; Anastomotic 
leakage; Lymph node 
retrieval; Completeness 
of resection/ margins of 
tumour clearance; 
Conversion; Wound 
infection; Urinary tract 
infection; 30 day 
mortality; Post-
operative pain; Survival; 
Disease-free survival; 
Recurrence 
Zheng 
2005[13](China) 
Single centre 
cohort matched 
Laparoscopic: 
30 
Open: 34 
27 
months 
(mean)  
26 
months 
(mean)  
Hospital Operation time; Blood 
loss; Specimen length; 
Lymph node yield; 
Pathological staging 
(Dukes’ staging); 
Analgesic requirements; 
Time to flatus passage; 
Time to resume normal 
diet; Duration of 
hospitalisation; 
Morbidity; Local 
recurrence rate; 
Metachronous 
metastasis rate; 
Mortality; Cumulative 
survival probability 
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Table 2 Cost data reported in the included studies 
Study id  Laparoscopic Open Difference (%) P value / 95% CI 
Franks 2005[14] 
(UK) 
Total cost £6900 £6632 £268 
(4.0) 
95% CI: -689 to 1458 
Perspective: 
Societal (£, price 
year not stated) 
Total costs, excl. 
productivity losses 
£5867 £5648 £229 
(4.0) 
Not available 
 Total costs, excl. 
prod losses & 
complications 
 
£5105 £5085 £20 
(0.0) 
Not available 
Franks 2005[14] 
(UK) (colon)) 
Total cost £5587 £5503 £84 
(1.5) 
95% CI: -642 to 792 
  (£, price year not 
stated) 
Total costs, excl. 
productivity losses 
£4640 £4728 -£88 
(-1.9) 
Not available 
Franks 2005[14] 
(UK) (rectum) 
Total cost £8260 £7820 £439 
(5.6) 
95% CI: -1294 to 
2857 
  (£, price year not 
stated) 
Total costs, excl. 
productivity losses 
£7148 £6595 £553 
(8.4) 
Not available 
Janson 
2004[11](Sweden) 
Total cost* €11,660 €9814 €1,846 
(18.8) 
P=0.104 
Perspective: 
Societal (€, 2001 
prices) 
Total costs, excl. 
productivity losses* 
€9474 €7235 €2,239 
(30.9) 
P=0.018 
 First admission* €6931 €5375 €1,556 
(28.9) 
P=0.015 
 Primary surgery*  €3493 €2322 €1,171 
(50.4) 
P=0.001 
King 2005[15] 
(UK) 
Total Cost £6433 £6790 -£357 
(-5.3) 
95%CI: -2167 to 2992 
Perspective: 
Societal (£, 2002) 
Total Costs – 
indirect costs 
£5,985 £6,068 -83 
(-1.4) 
NA 
 Theatre Costs £2885 £1964 £921 
(46.9) 
95%CI: 586 to 1251 
Leung 
2004[12](Hong 
Kong) 
Perspective: 
Hospital (USS 
dollar, price year 
not stated) 
Direct costs** USD9297 USD7148 USD2,149 
(30.1) 
P<0.001 
Zheng 
2005[13](China) 
Perspective: 
Hospital (Chinese 
renminbi, yuan, 
price year not 
stated) 
Total cost operation 
and drugs*** 
CNY11,499 
 (sd: 2619) 
CNY10,228 
 (sd: 2373) 
CNY1,271 
(12.4) 
P=0.131 
* €1 circa £0.66 (16) 
** USD1 circa £0.51 (16) 
*** CNY=Chinese Yuan (Renminbi); CNY1 circa £0.0658 (16) 
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Table 3  Incremental cost per unit of effectiveness avoided 
Outcome Study Incremental 
Cost 
Effectiveness 
Laparoscopic  (%) 
Effectiveness 
Open  (%) 
P value Incremental 
Effectiveness 
(%) 
ICER 
Mortality Janson 2004[11](Sweden)       
 Societal Perspective 1,846 € 1 0 NA 1.0% Open Dominates 
   (1.0) (0)    
 Health Service Perspective 2,239 € 1 0 NA 1.0% Open Dominates 
   (1.0) (0)    
 Leung 2004[12] (Hong Kong) USD 2,149 38 40 0.97 0.7% USD 307,000 
   (22.8) (23.5)    
5-years Survival Leung 2004[12] (Hong Kong) USD 2,149 76.1% 72.9% 0.61 3.2% USD 67,156 
5-years Disease 
Free Survival 
Leung 2004 [12] (Hong Kong) USD 2,149 75.3% 78.3% 0.45 3.0% Open Dominates 
Recurrence Leung 2004 [12](Hong Kong) USD 2,149 37 30 0.37 4.6% USD 46,717 
   (22.2) (17.6)    
Total 
Complications 
Franks 2005[14] (UK)       
 Societal Perspective £268 154 77 NA 0.1% USD 268,000 
   (35.7) (35.8)    
 Health Service Perspective £229 154 77 NA 0.1% USD 229,000 
   (35.7) (35.8)    
Major 
Complications 
Janson 2004[11] (Sweden)       
 Societal Perspective 1,846 € 33 26 NA 9.8% Open Dominates 
   (33) (23.2)    
 Health Service Perspective 2,239 € 33 26 NA 9.8% Open Dominates 
   (33) (23.2)    
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Table 3  Incremental cost per unit of effectiveness avoided (cont.) 
Outcome Study Incremental 
Cost 
Effectiveness 
Laparoscopic  (%) 
Effectiveness 
Open  (%) 
P value Incremental 
Effectiveness 
(%) 
ICER 
Major 
Complications 
Franks 2006[14] (UK)       
 Societal Perspective £268 62 23 NA 3.7% Open Dominates 
   (14.4) (10.7)    
 Health Service Perspective £229 62 23 NA 3.7% Open Dominates 
   (14.4) (10.7)    
 King 2006[15] (UK)       
 Societal Perspective -£357 6 5 0.208 11.0% Laparoscopic 
dominates 
   (15) (26)    
 NHS Perspective -£83 6 5 0.208 11.0% Laparoscopic 
dominates 
   (15) (26)    
 Zheng 2005[13] (China) CNY 1,271 5 10 0.23 12.7% CNY 10,008 
   (16.7) (29.4)    
Complications of 
surgery 
Leung 2004[12] (Hong Kong) USD 2,149 40 45 NA 2.8% USD 76,872 
   (19.7) (22.5)    
£=Pound Sterling; €=Euros; USD=US dollars; CNY=Chinese Yuan 
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Figure 1: Study selection flow diagram 
 
 
 
 
 
392 study hits
41 study abstracts selected for full 
assessment
3 met inclusion criteria
+
2 obtained from experts in 
the field
38 studies excluded:
• 12 background, editorial type 
paper
• 1 methodological article
• 7 covered by HTA 2000
• 5 not interventions of interest
• 6 not study group
• 7 only effects, no cost 
considered
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